References
- Moreno C, Montserrat E. Genetic lesions in chronic lymphocytic leukemia: What’s ready for prime time use? Haematologica. 2010; 95(1): 12-15.
- Demir V, Kahraman S, Katgı A, Pişkin Ö, Özsan GH, Demirkan F, et al. Kronik lenfositik lösemi hastalarının genel klinik değerlendirilmesi. J DEU Med Fac. 2012; 26(1): 9-19.
- Libisch MG, Casas M, Chiribao ML, Moreno P, Cayota A, Osinaga E, et al. GALNT11 as a new molecular marker in chronic lymphocytic leukemia. Gene. 2014; 533(1): 270-279.
- Langerbeins P, Groβ-Ophoff-Müller C, Herling CD. Risk-adapted therapy in early-stage chronic lymphocytic leukemia. Oncol Res Treat. 2016; 39(1-2): 18-24.
- Amaya-Chanaga CI, Rassenti LZ. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers. Best Pract Res Clin Haematol. 2016; 29(1): 79-89.
- Jones D. Neoplastic Hematopathology: Experimental and Clinical Approaches. Houston, TX, USA: Humana Press, 2010.
- Dunphy CH. Molecular Pathology of Hematolymphoid Diseases. Chapel Hill, NC, USA: Springer, 2010.
- Bottoni A, Calin GA. MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia. Microma. 2013; 2(3): 158-164.
- Shengkan J, Levine AJ. The p53 functional circuit. J Cell Sci. 2001; 114(23): 4139-4140.
- Harris SL, Levine AJ. The p53 pathway: Positive and negative feedback loops. Oncogene. 2005; 24(17): 2899-2908.
- Levine AJ. p53, The cellular gatekeeper for growth and division. Cell. 1997; 88(3): 323-331.
- RT2 Profiler PCR Array Data Analysis. 2017 https://dataanalysis.qiagen.com/pcr/arrayanalysis.php
- Goldin LR, Slager SL. Familial CLL: Genes and environment. Hematology Am Soc Hematol Educ Program. 2007: 339-345.
- Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26): 1910-1916.
- The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6): 779-790.
- Te Raa GD, Kater AP. TP53 dysfunction in CLL: Implications for prognosis and treatment. Best Pract Res Clin Haematol. 2016; 29(1): 90-99.
- Zenz T, Kröber A, Scherer A, Häbe S, Buhler A, Benner A, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood. 2008; 112(8): 3322-3329.
- Zenz T, Mertens D, Döhner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev. 2011; 25(3): 131-137.
- Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1997; 76(7): 935-938.
- Vucicevic K, Jakovljevic V, Sretenovic J, Tosic N, Kostic T, Glumac I, et al. Expression of the Bcl2 gene in chronic lymphocytic leukaemia patients. Ser J Exp Clin Res. 2015; 16(3): 187-191.
- Tsirigotis P, Pappa V, Labropoulos S, Papageorgiou S, Kontsioti F, Dervenoulas J, et al. Mutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia. Eur J Haematol. 2006; 76(3): 230-236.
- Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, MiuraY, Takeyama K, et al. Loss of the cyclin-dependent kinase 4-inhibitor (pl6; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood. 1995; 86(4): 1548-1556.
- Romagosa C, Simonetti S, López-Vicente L, Mazo A, Leonard ME, Castellvi J, et al. p 16Ink4a Overexpression in cancer: A tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011; 30(18): 2087-2097.
- Greco R, Sala E, Crucitti L, Morelli M, Stanghellini MTL, Vago L, et al. Pentraxin 3 as a novel diagnostic and prognostic biomarker for acute GvHD and fungal infections in adult allogeneic HSCT recipients. Blood. 2016; 128(22): 4600.
- Ke H-H, Hueng D-Y, Tsai W-C. Low expression of pentraxin 3 and nuclear factor-like 2 implying a relatively longer overall survival time in gliomas. Chin J Physiol. 2019; 62(1): 35-43.
- Liu B, Zhao Y, Guo L. Increased serum pentraxin-3 level predicts poor prognosis in patients with colorectal cancer after curative surgery, a cohort study. Medicine. 2018; 97(40): e11780.
- Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell. 2015; 160(4): 700-714.